E2F3 and neoplasm: Given that GSA or EASE cannot assign pathway activation status for individual tumor samples, we applied previously developed gene expression “readouts” resulting from experimentally controlled activation of specific oncogenic pathways (src, b-catenin and E2F3) that have been shown to bear prognostic relevance in ovarian cancer [12].